Citadel Advisors
IRD

Citadel Advisors’s Opus Genetics IRD Stock Holding History

Citadel Advisors’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,000
Closed -$982 – 15650
2025
Q1 		$982 Sell
1,000
-800
-44% -$894 ﹤0.01% 14187
2024
Q4 		$2.14K Buy
1,800
+1,000
+125% +$1.15K ﹤0.01% 14113
2024
Q3 		$1.05K Sell
800
-1,200
-60% -$1.85K ﹤0.01% 13912
2024
Q2 		$3.06K Sell
2,000
-4,200
-68% -$7.26K ﹤0.01% 13628
2024
Q1 		$12.5K Buy
6,200
+4,200
+210% +$10.7K ﹤0.01% 13359
2023
Q4 		$6.02K Sell
2,000
-8,900
-82% -$26.3K ﹤0.01% 13385
2023
Q3 		$36.5K Buy
10,900
+2,700
+33% +$10.8K ﹤0.01% 12107
2023
Q2 		$35.6K Buy
8,200
+6,600
+413% +$31.3K ﹤0.01% 12174
2023
Q1 		$6K Sell
1,600
-6,200
-79% -$22.3K ﹤0.01% 13833
2022
Q4 		$27.5K Buy
+7,800
New +$20.5K ﹤0.01% 12835
2022
Q1 		– Sell
-29,800
Closed -$111K – 14760
2021
Q4 		$111K Sell
29,800
-3,900
-12% -$15.6K ﹤0.01% 12613
2021
Q3 		$174K Buy
+33,700
New +$155K ﹤0.01% 12176

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's IRD Position: Q2 2026 in Review

Citadel Advisors increased its Opus Genetics (IRD) stake by 451% in Q2 2026, buying an estimated $2.54M and bringing the position to 665,662 shares worth $2.74M. The position accounts for ﹤0.01% of the portfolio, ranked #5859.

Citadel Advisors first reported a position in IRD in Q2 2013 and has held it in 29 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Citadel Advisors held 665,662 shares of Opus Genetics worth $2.74M as of Q2 2026.
  • Citadel Advisors bought 544,762 Opus Genetics shares in Q2 2026, an estimated $2.54M.
  • Opus Genetics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5859 holding.
  • Citadel Advisors first reported a position in Opus Genetics in Q2 2013 and has held it in 29 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.